How an Army of Pharma Lobbyists in Washington Have Locked in One of the Biggest Corporate Ripoff Schemes in America

‘After an 18-month investigation into the high cost of Gilead’s hepatitis C drug Sovaldi—initially listed at $84,000 for a course of treatment or $1,000 per pill—the Senate Finance Committee said the prices did not reflect the cost of research and development and that Gilead cared about “revenue” not “affordability and accessibility.” That sounds like an understatement. Sovaldi and the related pill Harvoni cost Medicare and Medicaid more than $5 billion in 2014, charged senators.

But Gilead is far from the only drug company camping out on our tax dollars. In the 2000s, atypical antipsychotics were widely prescribed to children with behavior problems enrolled in Medicaid programs provoking lawsuits from states as their budgets were sacked.’

Read more: How an Army of Pharma Lobbyists in Washington Have Locked in One of the Biggest Corporate Ripoff Schemes in America

The post How an Army of Pharma Lobbyists in Washington Have Locked in One of the Biggest Corporate Ripoff Schemes in America appeared first on David Icke.